INTRODUCTION
Young and middle-aged adults constitute a special population in aortic valve surgery. Owing to a longer anticipated life expectancy, these patients present a higher lifetime risk of prosthesisrelated complications. The ideal aortic valve substitute in this patient population should therefore allow (1) improved survival, (2) avoidance of reoperation, and (3) avoidance of prosthesisrelated complications. The ideal aortic valve substitute in young and middle-aged adults remains elusive. Due to their durability, mechanical prostheses are the most frequently used option. However, their use requires lifelong anticoagulation. Recent reports suggest excess in longterm mortality in young patients who undergo mechanical aortic valve replacement (AVR) when compared to the general population [1] .
The Ross procedure (pulmonary autograft replacement) is the replacement of the diseased aortic valve with the patient's own pulmonary valve. A pulmonary homograft is placed in the pulmonary position. This procedure alleviates the need for lifelong anticoagulation. It allows for the replacement of the diseased aortic valve with a living valve, thus conferring a hemodynamic profile similar to that of the native aortic valve. The Ross procedure has been the object of much criticism, due to the complexity of surgical implantation, exposition to a broad spectrum of complex reoperations, and the notion of transforming a univalvular disease into a bivalvular disease [2] . As a result, the routine use of this procedure has not gained widespread adoption and is limited to a few centers worldwide.
There is a paucity of data comparing outcomes between the Ross procedure and mechanical AVR in adults [3] [4] [5] [6] and no randomized trial on this matter has been conducted to date. Furthermore, no longitudinal study comparing long-term (≥20 years) outcomes between these two techniques has been published to date. The purpose of the study reported herein was to compare long-term outcomes of the Ross procedure versus mechanical AVR in terms of survival, freedom from reoperation and freedom from adverse valve-related events.
METHODS

Patient Population
Between February 1990 and August 2014, 258 consecutive patients underwent a Ross procedure and 1,444 a mechanical AVR at a single institution. Patients with acute aortic dissection, active endocarditis, or requiring emergency surgery were excluded from the present study. To mitigate the effects of measurable baseline confounders, patients were matched into 208 pairs using propensity score matching. Baseline characteristics of the propensity-matched cohort are available in Table 1 . Mean age was 37.2 ± 10.2 years (range: 16 to 63 years) and 63% were male.
Data Sources
This observational single-center, cohort study was approved by the Review Ethics Board of University Health Network (Toronto, ON, Canada) and a waiver of consent was obtained. Perioperative data were entered prospectively in an institutional clinical database. Patients were prospectively followed annually during the first decade and biennially thereafter. Additional follow-up information was obtained through comprehensive questionnaires and by telephone interview with surviving patients, family members, or the patient's personal physician. The study was closed on September 1, 2014. Clinical follow-up was available in 98.8% of patients at a mean of 14.4 ± 6.4 years postoperatively (range: 1 to 26 years), representing a total of 5906 patient-years. Mean follow-up was 13.6 ± 5.8 years in the Ross group and 15.1 ± 7.0 years in the mechanical aortic valve replacement group (p = 0.02).
Study Outcomes
All outcomes of interest were recorded and reported according to the Society of Thoracic Surgery Guidelines for Reporting Mortality and Morbidity Mortality After Cardiac Valve
Interventions [7] . The primary outcome of this study was death from any cause and was divided into early mortality (occurring within 30 days of surgery or during the index hospitalization) and late mortality. Mortality was classified as valve-related, cardiac-related, or non-cardiac. All sudden or unknown causes of death were considered valve-related. Secondary outcomes were valve reoperation, thromboembolic events (stroke and transient ischemic attack), and significant hemorrhage, which was defined as major bleeding leading to death, stroke or requiring hospitalization and/or transfusion. Where applicable, outcomes of interest in the Ross group were considered for both the aortic and pulmonary positions.
Statistical Analyses
The propensity score was constructed with the use of a non-parsimonious multivariable logistic regression model. In this model, the choice of operation (Ross vs mechanical AVR) was the dependent variable and the covariates in Table 1 were included as independent variables. Patients were matched according to the method of nearest neighbour matching. A propensity score difference of 0.05 was used as a maximum caliper width for matching the two treatment groups. All statistical analyses were performed with SAS statistical software version 9.1 (SAS Institute, Inc, Cary, NC). Continuous data are expressed as mean ± standard deviation, and categorical variables are presented as frequency (%). Skewed variables are expressed as median (interquartile range). Differences between continuous variables were tested using Student's t-test when normally distributed. Otherwise, a nonparametric test was used. Categorical variables were compared using a Chi-square test or Fisher's exact test, as appropriate. Survival and freedom from late adverse events curves were obtained using the Kaplan-Meier method. Survival and late outcomes were compared between groups by means of the log-rank test or Breslow's test, as appropriate.
RESULTS
Survival
Rates of early mortality were similar between the two matched groups with one early death in each group (Ross: 0.5%; AVR: 0.5%, p=1.0). In the cohort of 208 matched pairs, during 5906 patient-years of follow-up, a total of 35 patients died. In the Ross group, the total number of deaths was 13, including 12 late deaths; in the AVR group, the total number of deaths was 22, including 21 late deaths. Survival at various time points is presented in Table 2 . In the Ross group, late mortality was valve-related in 3 patients (sudden/unexplained death [n=2], endocarditis [n=1]) and non-cardiac in 9 patients. In the AVR group, late mortality was valverelated in 12 patients (sudden/unexplained death [n=6], stroke/major bleeding [n=3], death at valve reintervention [n=2], congestive heart failure secondary to aortic valve disease [n=1]), cardiac in 4 patients and non-cardiac in 5 patients. There was a trend towards lower rates of valve-related mortality in the Ross group (p=0.06). The cumulative survival for each group is depicted in Figure 1 . At 20 years, there was no difference in survival between the groups (p=0.36).
Valve Reintervention
In the Ross group, the total number of patients who required one or more valve reintervention was 17. Fourteen patients had a single reintervention, two patients had two and one patient had three. Fourteen patients had reintervention on the pulmonary autograft. The indication for reintervention was structural deterioration in 10 patients, non-structural dysfunction in three (annular dilatation [n=1], sinotubular junction dilatation [n=1], subaortic false aneurysm [n=1]), and endocarditis in one. Reintervention consisted of tissue AVR in seven patients, mechanical AVR in three, pulmonary autograft repair/resuspension in two, aortic homograft implantation in one and subaortic false aneurysm repair in one. Seven patients had reintervention on the pulmonary homograft, either combined with pulmonary autograft surgery (three patients) or in isolation (four patients). The indication for pulmonary homograft reintervention was structural deterioration in five patients and endocarditis in two. Reintervention consisted of new pulmonary homograft implantation (five patients), stentless bioprosthesis implantation (one patient) and percutaneous pulmonary valve replacement (two patients).
In the mechanical AVR group, the total number of patients who required one or more aortic valve reintervention was 10. Nine patients had a single reintervention and one patient had two. The indication for reintervention was prosthetic valve endocarditis in four patients, valve thrombosis in two, structural valve deterioration (prosthetic aortic valve dehiscence) in one, and non-structural valve dysfunction in three (pannus [n=2], left ventricular outflow tract pseudoaneurysm [n=1]). Reintervention consisted of mechanical valve replacement in eight patients, and aortic homograft implantation in two.
Freedom from operated valve reintervention at various time points is presented in Table 2 . For The cumulative freedom from reintervention for each group is depicted in Figure 2 . At 20 years, there was no difference in freedom from valve reintervention between the groups (p = 0.14).
Thromboembolic and Hemorrhagic Complications
Freedom from cerebral thromboembolism at various time points is presented in Table 2 . Five cases of cerebral thromboembolism were reported in four patients in the Ross group (three transient ischemic attacks, two ischemic strokes). One stroke showed complete recovery, one led to permanent deficit. There were no fatal strokes in the Ross group. By contrast, 33 cases of cerebral thromboembolism were reported in 26 patients in the mechanical AVR group (20 transient ischemic attacks, 13 ischemic strokes). Of the 13 strokes, five recovered completely, five led to permanent deficit and three were fatal.
Freedom from major bleeding at various time points is presented in Table 2 . No bleeding events were reported in the Ross group, including in patients who subsequently underwent mechanical AVR for pulmonary autograft failure. A total of 27 major bleeding events were reported in 23 patients in the mechanical AVR group. Of these, two were fatal, two manifested as hemorrhagic stroke and 23 led to hospitalization and/or transfusion.
The cumulative freedom from stroke (transient ischemic attacks not included) or major bleeding for each group is depicted in Figure 3D . Freedom from these complications was superior after the Ross procedure (p<0.001).
CONCLUSIONS
The major finding from this study is that the Ross procedure is associated with significantly lower rates of thromboembolic and hemorrhagic complications compared to mechanical AVR. These differences did not, however, translate into differences in long-term survival between the two groups. In a propensity-matched cohort study with a mean follow-up of 5.7 years, Mokhles et al. similarly reported equivalent survival between the Ross procedure and mechanical AVR [5] . Our study suggests that this equivalent survival extends up to 20 years after surgery. However, there was a strong trend towards lower rates of valve-related mortality with the use of the Ross procedure. Of note, the Ross procedure was associated with a very low immediate operative risk, similar to that of mechanical AVR. Furthermore, despite significant differences in modes of failure, freedom from long-term valve reintervention was not significantly different between the two strategies. Collectively, these data suggest that in specialized centers, the Ross procedure represents an excellent option for young and middle-aged adults undergoing aortic valve replacement. 
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